SOURCE: SynCardia Systems, Inc.

SynCardia Systems, Inc.

April 26, 2011 09:55 ET

BBC's Flagship Science TV Series "Horizon" Features Patient With SynCardia's Total Artificial Heart

BBC Visits Drs. Long & Horstmanshof at INTEGRIS Baptist Medical Center and Total Artificial Heart Patient Waiting at Home for a Matching Donor Heart

TUCSON, AZ--(Marketwire - Apr 26, 2011) - SynCardia Systems, Inc., manufacturer of the SynCardia temporary Total Artificial Heart, announced today that the BBC's flagship science series, "Horizon," is airing an episode that includes a segment featuring a Total Artificial Heart patient waiting at home for a matching donor heart using the Freedom® portable driver.

During the 60-minute episode titled "How To Mend A Broken Heart," the show's host Dr. Kevin Fong, visits cardiovascular surgeon James Long, MD, and heart failure cardiologist Douglas Horstmanshof, MD, at INTEGRIS Baptist Medical Center in Oklahoma City to learn more about the world's first and only FDA, Health Canada and CE approved Total Artificial Heart.

"This thing needs to be implanted in a human being," says Dr. Fong, holding SynCardia's Total Artificial Heart. "It needs to work seamlessly and reliably for millions of beats. The valves must never stick, blood must flow over its surfaces without clotting, the pump must never leak and a person's life totally depends upon it."

Dr. Horstmanshof drives Dr. Fong to Geary, Okla. to meet 45-year-old Troy Golden, a registered nurse and pastor who has been living with the Total Artificial Heart since September 2010. A month after implant, Mr. Golden was discharged from the hospital to wait for a matching donor heart at home using the Freedom portable driver.

Mr. Golden is participating in an FDA-approved Investigational Device Exemption (IDE) clinical study of the Freedom driver. Weighing 13.5 lbs, it's the first U.S. portable driver designed to power SynCardia's Total Artificial Heart both inside and outside the hospital. Wearing the Freedom driver in the Backpack, Mr. Golden was able to return to the pulpit and preach at his church two months after receiving the Total Artificial Heart.

"It's mind-blowing to think that where he once had a heart, there's now a mechanical device," says Dr. Fong. "That it's been replaced with plastic and tubes attached to a pneumatic pump inside the rucksack on his back."

To watch the episode on YouTube, please visit http://youtu.be/osos8dv5rqc. The segment begins approximately 8 min. 15 sec. into the video.

About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Similar to a heart transplant, the SynCardia temporary Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers and does not require expensive anti-rejection medication, which can cause subsequent complications.

Originally used as a permanent replacement heart, SynCardia's Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 900 implants of the Total Artificial Heart, accounting for more than 210 patient years of life. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through both ventricles.

SynCardia Ranked #20 Among World's 50 Most Innovative Companies
In March 2011, Fast Company magazine ranked SynCardia #20 in its annual list of the world's 50 Most Innovative Companies for "giving mobility to artificial heart recipients." Weighing 13.5 lbs, SynCardia's Freedom® portable driver is the world's first wearable driver for powering the Total Artificial Heart both inside and outside the hospital. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.

For additional information, please visit: http://www.syncardia.com or follow SynCardia on Twitter -- @SynCardia_News

Contact Information

  • Media Contact:
    Don Isaacs
    Vice President of Communications
    SynCardia Systems, Inc.
    Cell: (520) 955-0660